Engineered in-situ depot-forming hydrogels for intratumoral drug delivery

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 465-475

  Fakhari, Amir ^a   Anand Subramony, J ^a  

^a MEDIMMUNE   (United States)

Author keywords

Anticancer drug; Biologics sustained release; Engineered hydrogel; In situ gelling; Intratumoral drug delivery

Indexed keywords

BIOCHEMISTRY; CHEMOTHERAPY; GELATION; PHARMACOKINETICS; TOXICITY; TUMORS;

ANTICANCER DRUG; BIOLOGICAL MOLECULE; DRUG DELIVERY TECHNOLOGIES; DRUG DISTRIBUTION; IN-SITU-GELLING; INTRATUMORAL DRUG DELIVERIES; SUSTAINED RELEASE; SYSTEMIC TOXICITIES;

HYDROGELS;

ANTINEOPLASTIC AGENT; CHITOSAN; CISPLATIN; DEXTRAN; DOXORUBICIN; FLUOROURACIL; GENDICINE; HYALURONIC ACID; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; LEUPRORELIN; MACROGOL; METHYLCELLULOSE; OPORTUZUMAB MONATOX; PACLITAXEL; PEXASTIMOGENE DEVACIREPVEC; POLOXAMER; POLYGLACTIN; SOLVENT; TALIMOGENE LAHERPAREPVEC; TAMOXIFEN CITRATE; TOPOTECAN; DELAYED RELEASE FORMULATION; DRUG CARRIER; HYDROGEL; ONCOLYTIC VIRUS; POLYMER;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COLON CANCER; CROSS LINKING; DRUG DELIVERY SYSTEM; GELATION; HEAD AND NECK CANCER; HEAT SENSITIVITY; HUMAN; HYDROGEL; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE SEPARATION; POLYMERIZATION; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SOLID TUMOR; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; GENE THERAPY; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROCEDURES; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; GENETIC THERAPY; HUMANS; HYDROGELS; INJECTIONS, INTRALESIONAL; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLYMERS;

EID: 84947281988     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.014     Document Type: Review

References (136)

1. B.D. Weinberg, E. Blanco, and J. Gao Polymer implants for intratumoral drug delivery and cancer therapy J. Pharm. Sci. 97 2008 1681 1702
2. J. Crawford, D.C. Dale, and G.H. Lyman Chemotherapy-induced neutropenia Cancer 100 2004 228 237
3. K.B. Wallace Doxorubicin-induced cardiac mitochondrionopathy Pharmacol. Toxicol. 93 2003 105 115
4. Y. Brudno, and D.J. Mooney On-demand drug delivery from local depots J. Control. Release 2015
5. J.B. Wolinsky, Y.L. Colson, and M.W. Grinstaff Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers J. Control. Release 159 2012 14 26
6. B. Kwong, H. Liu, and D.J. Irvine Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy Biomaterials 32 2011 5134 5147
7. B. Kwong, S.A. Gai, J. Elkhader, K.D. Wittrup, and D.J. Irvine Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity Cancer Res. 73 2013 1547 1558
8. S. Kempe, and K. Mäder In situ forming implants - an attractive formulation principle for parenteral depot formulations J. Control. Release 161 2012 668 679
9. X. Liu, W.S. Heng, Q. Li, and L.W. Chan Novel polymeric microspheres containing norcantharidin for chemoembolization J. Control. Release 116 2006 35 41
10. T. Abe, M. Sakane, T. Ikoma, M. Kobayashi, S. Nakamura, and N. Ochiai Intraosseous delivery of paclitaxel-loaded hydroxyapatitealginate composite beads delaying paralysis caused by metastatic spine cancer in rats: laboratory investigation J. Neurosurg. Spine 9 2008 502 510
11. K.H. Bouhadir, E. Alsberg, and D.J. Mooney Hydrogels for combination delivery of antineoplastic agents Biomaterials 22 2001 2625 2633
12. A.M. Al-Ghananeem, A.H. Malkawi, Y.M. Muammer, J.M. Balko, E.P. Black, W. Mourad, and E. Romond Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations AAPS PharmSciTech 10 2009 410 417
13. D.E. Gerber, G.L. Gallia, B.M. Tyler, C.G. Eberhart, G. Royer, and S.A. Grossman A novel polymer gel for the delivery of local therapies to intracranial tumors: in vivo safety evaluation J. Biomed. Mater. Res. A 99 2011 479 484
14. X. Li, X. Kong, J. Zhang, Y. Wang, Y. Wang, S. Shi, G. Guo, F. Luo, X. Zhao, and Y. Wei A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids J. Pharm. Sci. 100 2011 232 241
15. L. Ampollini, F. Sonvico, E. Barocelli, A. Cavazzoni, R. Bilancia, C. Mucchino, A.M. Cantoni, and P. Carbognani Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study Eur. J. Cardiothorac. Surg. 37 2010 557 565
16. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother. Pharmacol. 60 2007 907 914
17. B.S. Davidson, F. Izzo, D.M. Cromeens, L.C. Stephens, Z.H. Siddik, and S.A. Curley Collagen matrix cisplatin prevents local tumor growth after margin-positive resection J. Surg. Res. 58 1995 618 624
18. B.A. Almond, A.R. Hadba, S.T. Freeman, B.J. Cuevas, A.M. York, C.J. Detrisac, and E.P. Goldberg Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer J. Control. Release 91 2003 147 155
19. S. Kakinoki, and T. Taguchi Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride Eur. J. Pharm. Biopharm. 67 2007 676 681
20. J.R. McDaniel, D.J. Callahan, and A. Chilkoti Drug delivery to solid tumors by elastin-like polypeptides Adv. Drug Deliv. Rev. 62 2010 1456 1467
21. M. Konishi, Y. Tabata, M. Kariya, A. Suzuki, M. Mandai, K. Nanbu, K. Takakura, and S. Fujii In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel J. Control. Release 92 2003 301 313
22. K. Stuart, K. Stokes, R. Jenkins, C. Trey, and M. Clouse Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization Cancer 72 1993 3202 3209
23. C. Alvarez-Lorenzo, B. Blanco-Fernandez, A.M. Puga, and A. Concheiro Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery Adv. Drug Deliv. Rev. 65 2013 1148 1171
24. L. Yu, and J. Ding Injectable hydrogels as unique biomedical materials Chem. Soc. Rev. 37 2008 1473 1481
25. A. Fakhari, Q. Phan, and C. Berkland Hyaluronic acid colloidal gels as self-assembling elastic biomaterials J. Biomed. Mater. Res. B Appl. Biomater. 102 2014 612 618
26. D.J. Overstreet, D. Dutta, S.E. Stabenfeldt, and B.L. Vernon Injectable hydrogels J. Polym. Sci. B Polym. Phys. 50 2012 881 903
27. M.K. Nguyen, and D.S. Lee Injectable biodegradable hydrogels Macromol. Biosci. 10 2010 563 579
28. A.H. Van Hove, and D.S. Benoit Depot-based delivery systems for pro-angiogenic peptides: a review Front. Bioeng. Biotechnol. 3 2015
29. R.B. Weiss, R. Donehower, P. Wiernik, T. Ohnuma, R. Gralla, D. Trump, J. Baker, D. Van Echo, D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268
30. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
31. A. Sparreboom, O. van Tellingen, W.J. Nooijen, and J.H. Beijnen Tissue distribution, metabolism and excretion of paclitaxel in mice Anti-Cancer Drugs 7 1996 78 86
32. S.E. Shackney, G.W. McCORMACK, and G.J. Cuchural Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review Ann. Intern. Med. 89 1978 107 121
33. J.S. Meyer Cell kinetic measurements of human tumors Hum. Pathol. 13 1982 874 877
34. C. Packhaeuser, J. Schnieders, C. Oster, and T. Kissel In situ forming parenteral drug delivery systems: an overview Eur. J. Pharm. Biopharm. 58 2004 445 455
35. D. Chitkara, A. Shikanov, N. Kumar, and A.J. Domb Biodegradable injectable in situ depot-forming drug delivery systems Macromol. Biosci. 6 2006 977 990
36. M. Dittgen, S. Fricke, H. Gerecke, I. Möller, C. Völkel, Injection Implant, Germany Patent WO/1998/030245, (1998).
37. R. Vaishya, V. Khurana, S. Patel, and A.K. Mitra Long-term delivery of protein therapeutics Expert Opin. Drug Deliv. 12 2015 415 440
38. A.K. Burkoth, and K.S. Anseth A review of photocrosslinked polyanhydrides: in situ forming degradable networks Biomaterials 21 2000 2395 2404
39. S.-Y. Lee, and G. Tae Formulation and in vitro characterization of an in situ gelable, photo-polymerizable Pluronic hydrogel suitable for injection J. Control. Release 119 2007 313 319
40. J. Berger, M. Reist, J.M. Mayer, O. Felt, N. Peppas, and R. Gurny Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications Eur. J. Pharm. Biopharm. 57 2004 19 34
41. F.L. Mi, S.S. Shyu, C.Y. Kuan, S.T. Lee, K.T. Lu, and S.F. Jang Chitosan - polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. I. Effect of phosphorous polyelectrolyte complex and enzymatic hydrolysis of polymer J. Appl. Polym. Sci. 74 1999 1868 1879
42. K. Anseth, S. Newman, and C. Bowman Polymeric dental composites: properties and reaction behavior of multimethacrylate dental restorations Biopolymers Ii 1995 Springer 177 217
43. J.A. Burdick, L.M. Philpott, and K.S. Anseth Synthesis and characterization of tetrafunctional lactic acid oligomers: a potential in situ forming degradable orthopaedic biomaterial J. Polym. Sci. A Polym. Chem. 39 2001 683 692
44. J.A. Burdick, R.F. Padera, J.V. Huang, and K.S. Anseth An investigation of the cytotoxicity and histocompatibility of in situ forming lactic acid based orthopedic biomaterials J. Biomed. Mater. Res. 63 2002 484 491
45. T. Vermonden, N.E. Fedorovich, D. van Geemen, J. Alblas, C.F. van Nostrum, W.J. Dhert, and W.E. Hennink Photopolymerized thermosensitive hydrogels: synthesis, degradation, and cytocompatibility Biomacromolecules 9 2008 919 926
46. B. Balakrishnan, and A. Jayakrishnan Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffolds Biomaterials 26 2005 3941 3951
47. J.B. Leach, and C.E. Schmidt Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds Biomaterials 26 2005 125 135
48. A.S. Sawhney, C.P. Pathak, J.J. van Rensburg, R.C. Dunn, and J.A. Hubbell Optimization of photopolymerized bioerodible hydrogel properties for adhesion prevention J. Biomed. Mater. Res. 28 1994 831 838
49. K. Obara, M. Ishihara, Y. Ozeki, T. Ishizuka, T. Hayashi, S. Nakamura, Y. Saito, H. Yura, T. Matsui, and H. Hattori Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice J. Control. Release 110 2005 79 89
50. A. Wadee, V. Pillay, Y.E. Choonara, L.C. du Toit, C. Penny, V.M. Ndesendo, P. Kumar, and C.S. Murphy Recent advances in the design of drug-loaded polymeric implants for the treatment of solid tumors Expert Opin. Drug Deliv. 8 2011 1323 1340
51. L. Pescosolido Interpenetrating Polymer Network Hydrogels Based on Polysaccharides for Biomedical Applications 2011
52. A. Hatefi, and B. Amsden Biodegradable injectable in situ forming drug delivery systems J. Control. Release 80 2002 9 28
53. M. Hamdine, M.-C. Heuzey, and A. Bégin Viscoelastic properties of phosphoric and oxalic acid-based chitosan hydrogels Rheol. Acta 45 2006 659 675
54. M. Nickerson, J. Patel, D. Heyd, D. Rousseau, and A. Paulson Kinetic and mechanistic considerations in the gelation of genipin-crosslinked gelatin Int. J. Biol. Macromol. 39 2006 298 302
55. S. Emoto, H. Yamaguchi, T. Kamei, H. Ishigami, T. Suhara, Y. Suzuki, T. Ito, J. Kitayama, and T. Watanabe Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer Surg. Today 44 2014 919 926
56. A. Bernkop-Schnürch, A.H. Krauland, V.M. Leitner, and T. Palmberger Thiomers: potential excipients for non-invasive peptide delivery systems Eur. J. Pharm. Biopharm. 58 2004 253 263
57. A. Vashist, A. Vashist, Y. Gupta, and S. Ahmad Recent advances in hydrogel based drug delivery systems for the human body J. Materi. Chem. B 2 2014 147 166
58. P. Agarwal, and I.D. Rupenthal Injectable implants for the sustained release of protein and peptide drugs Drug Discov. Today 18 2013 337 349
59. A. Bernkop-Schnürch, and S. Dünnhaupt Chitosan-based drug delivery systems Eur. J. Pharm. Biopharm. 81 2012 463 469
60. W. Zhu, Y. Li, L. Liu, Y. Chen, C. Wang, and F. Xi Supramolecular hydrogels from cisplatin-loaded block copolymer nanoparticles and α-cyclodextrins with a stepwise delivery property Biomacromolecules 11 2010 3086 3092
61. G.W. Bos, J.J. Jacobs, J.W. Koten, S. Van Tomme, T. Veldhuis, C.F. van Nostrum, W. Den Otter, and W.E. Hennink In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy Eur. J. Pharm. Sci. 21 2004 561 567
62. C. Hiemstra, Z. Zhong, S.R. Van Tomme, M.J. van Steenbergen, J.J. Jacobs, W. Den Otter, W.E. Hennink, and J. Feijen In vitro and in vivo protein delivery from in situ forming poly (ethylene glycol)-poly (lactide) hydrogels J. Control. Release 119 2007 320 327
63. N. Bhattarai, J. Gunn, and M. Zhang Chitosan-based hydrogels for controlled, localized drug delivery Adv. Drug Deliv. Rev. 62 2010 83 99
64. Y. Qiu, and K. Park Environment-sensitive hydrogels for drug delivery Adv. Drug Deliv. Rev. 64 2012 49 60
65. F. Tirnaksiz, and J. Robinson Rheological, mucoadhesive and release properties of pluronic F-127 gel and pluronic F-127/polycarbophil mixed gel systems Die Pharmazie-An Int. J. Pharm. Sci. 60 2005 518 523
66. J. Berger, M. Reist, J.M. Mayer, O. Felt, and R. Gurny Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications Eur. J. Pharm. Biopharm. 57 2004 35 52
67. W. Wu, H. Chen, F. Shan, J. Zhou, X. Sun, L. Zhang, and T. Gong A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery Mol. Pharm. 11 2014 3378 3385
68. R.E. Eliaz, and J. Kost Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins J. Biomed. Mater. Res. 50 2000 388 396
69. L. Zhao, L. Zhu, F. Liu, C. Liu, Q. Wang, C. Zhang, J. Li, J. Liu, X. Qu, and Z. Yang pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel Int. J. Pharm. 410 2011 83 91
70. L. Li, J. Gu, J. Zhang, Z. Xie, Y. Lu, L. Shen, Q. Dong, and Y. Wang Injectable and biodegradable pH-responsive hydrogels for localized and sustained treatment of human fibrosarcoma ACS Appl. Mater. Interfaces 7 2015 8033 8040
71. H.J. Moon, M.H. Park, M.K. Joo, and B. Jeong Temperature-responsive compounds as in situ gelling biomedical materials Chem. Soc. Rev. 41 2012 4860 4883
72. O. Sartor, M.K. Dineen, R. Perez-Marreno, F.M. Chu, G.J. Carron, and R.C. Tyler An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer Urology 62 2003 319 323
73. E. Ruel-Gariépy, and J.-C. Leroux In situ-forming hydrogels - review of temperature-sensitive systems Eur. J. Pharm. Biopharm. 58 2004 409 426
74. M.K. Joo, M.H. Park, B.G. Choi, and B. Jeong Reverse thermogelling biodegradable polymer aqueous solutions J. Mater. Chem. 19 2009 5891 5905
75. C. He, S.W. Kim, and D.S. Lee In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery J. Control. Release 127 2008 189 207
76. Y. Liu, W.-L. Lu, J.-C. Wang, X. Zhang, H. Zhang, X.-Q. Wang, T.-Y. Zhou, and Q. Zhang Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization J. Control. Release 117 2007 387 395
77. A. Sosnik, D. Cohn, J.S. Román, and G.A. Abraham Crosslinkable PEO-PPO-PEO-based reverse thermo-responsive gels as potentially injectable materials J. Biomater. Sci. Polym. Ed. 14 2003 227 239
78. A. Sosnik, and D. Cohn Reverse thermo-responsive poly (ethylene oxide) and poly (propylene oxide) multiblock copolymers Biomaterials 26 2005 349 357
79. D. Coughlan, and O. Corrigan Drug-polymer interactions and their effect on thermoresponsive poly (N-isopropylacrylamide) drug delivery systems Int. J. Pharm. 313 2006 163 174
80. C.T. Huynh, M.K. Nguyen, and D.S. Lee Injectable block copolymer hydrogels: achievements and future challenges for biomedical applications Macromolecules 44 2011 6629 6636
81. M.H. Park, M.K. Joo, B.G. Choi, and B. Jeong Biodegradable thermogels Acc. Chem. Res. 45 2011 424 433
82. B. Jeong, S.W. Kim, and Y.H. Bae Thermosensitive sol-gel reversible hydrogels Adv. Drug Deliv. Rev. 54 2002 37 51
83. G. Dumortier, J.L. Grossiord, F. Agnely, and J.C. Chaumeil A review of poloxamer 407 pharmaceutical and pharmacological characteristics Pharm. Res. 23 2006 2709 2728
84. W. Pan, and Z. Yang Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies Int. J. Nanomedicine 6 2011 151 166
85. Z. Lin, W. Gao, H. Hu, K. Ma, B. He, W. Dai, X. Wang, J. Wang, X. Zhang, and Q. Zhang Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: high drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity J. Control. Release 174 2014 161 170
86. T. Hayashi, B. Crain, M. Corr, M. Chan, H.B. Cottam, R. Maj, A. Barberis, L. Leoni, and D.A. Carson Intravesical toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer Int. J. Urol. 17 2010 483 490
87. C. Ju, J. Sun, P. Zi, X. Jin, and C. Zhang Thermosensitive micelles-hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel J. Pharm. Sci. 102 2013 2707 2717
88. A. Alexander, J. Khan, S. Saraf, and S. Saraf Poly (ethylene glycol)-poly (lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications J. Control. Release 172 2013 715 729
89. G.M. Zentner, R. Rathi, C. Shih, J.C. McRea, M.-H. Seo, H. Oh, B. Rhee, J. Mestecky, Z. Moldoveanu, and M. Morgan Biodegradable block copolymers for delivery of proteins and water-insoluble drugs J. Control. Release 72 2001 203 215
90. N.L. Elstad, and K.D. Fowers OncoGel (ReGel/paclitaxel) - clinical applications for a novel paclitaxel delivery system Adv. Drug Deliv. Rev. 61 2009 785 794
91. S.J. Vukelja, S.P. Anthony, J.C. Arseneau, B.S. Berman, C.C. Cunningham, J.J. Nemunaitis, W.E. Samlowski, and K.D. Fowers Phase 1 study of escalating-dose OncoGel®(ReGel®/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions Anti-Cancer Drugs 18 2007 283 289
92. G.A. DuVall, D. Tarabar, R.H. Seidel, N.L. Elstad, and K.D. Fowers Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer Anti-Cancer Drugs 20 2009 89 95
93. B. Choi, X.J. Loh, A. Tan, C.K. Loh, E. Ye, M.K. Joo, and B. Jeong Introduction to in situ forming hydrogels for biomedical applications In-Situ Gelling Polymers 2015 Springer 5 35
94. W.E. Samlowski, J.R. McGregor, M. Jurek, M. Baudys, G.M. Zentner, and K.D. Fowers ReGel® polymer-based delivery of interleukin-2 as a cancer treatment J. Immunother. 29 2006 524 535
95. G. Chang, T. Ci, L. Yu, and J. Ding Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel J. Control. Release 156 2011 21 27
96. Y.-M. Chung, K.L. Simmons, A. Gutowska, and B. Jeong Sol-gel transition temperature of PLGA-g-PEG aqueous solutions Biomacromolecules 3 2002 511 516
97. B. Jeong, L.-Q. Wang, and A. Gutowska Biodegradable thermoreversible gelling PLGA-g-PEG copolymers Electronic supplementary information (ESI) available: 1 H NMR spectrum of PLGA-g-PEG in CDCl3. 13C NMR (75 MHz) spectra of 25 wt.% PLGA-g-PEG copolymer in D2O as a function of T. See http://www. rsc. org/suppdata/cc/b1/b102819g Chem. Commun. 2001 1516 1517
98. H. Hyun, Y.H. Kim, I.B. Song, J.W. Lee, M.S. Kim, G. Khang, K. Park, and H.B. Lee In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier Biomacromolecules 8 2007 1093 1100
99. X.J. Loh, B.J.H. Yee, and F.S. Chia Sustained delivery of paclitaxel using thermogelling poly (PEG/PPG/PCL urethane) s for enhanced toxicity against cancer cells J. Biomed. Mater. Res. A 100 2012 2686 2694
100. J.Y. Lee, K.S. Kim, Y.M. Kang, E.S. Kim, S.-J. Hwang, H.B. Lee, B.H. Min, J.H. Kim, and M.S. Kim In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth Int. J. Pharm. 392 2010 51 56
101. Y.M. Kang, G.H. Kim, J.I. Kim, B.N. Lee, S.M. Yoon, J.H. Kim, and M.S. Kim In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly (ethylene glycol)-b-polycaprolactone diblock copolymer Biomaterials 32 2011 4556 4564
102. S. Xu, W. Wang, X. Li, J. Liu, A. Dong, and L. Deng Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX · HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency Eur. J. Pharm. Sci. 62 2014 267 273
103. H.W. Seo, D.Y. Kwon, J.S. Kwon, L.M. Jin, B. Lee, J.H. Kim, B.H. Min, and M.S. Kim Injectable intratumoral hydrogel as 5-fluorouracil drug depot Biomaterials 34 2013 2748 2757
104. G.D. Kang, S.H. Cheon, and S.-C. Song Controlled release of doxorubicin from thermosensitive poly (organophosphazene) hydrogels Int. J. Pharm. 319 2006 29 36
105. A.M. Al-Abd, K.-Y. Hong, S.-C. Song, and H.-J. Kuh Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice J. Control. Release 142 2010 101 107
106. A. Shikanov, S. Shikanov, B. Vaisman, J. Golenser, and A.J. Domb Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant Int. J. Pharm. 358 2008 114 120
107. A. Shikanov, B. Vaisman, S. Shikanov, and A.J. Domb Efficacy of poly (sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel J. Biomed. Mater. Res. A 92 2010 1283 1291
108. K. Kobayashi, C.-i. Huang, and T.P. Lodge Thermoreversible gelation of aqueous methylcellulose solutions Macromolecules 32 1999 7070 7077
109. D. Gupta, C.H. Tator, and M.S. Shoichet Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord Biomaterials 27 2006 2370 2379
110. J.K. Kim, Y.-W. Won, K.S. Lim, and Y.-H. Kim Low-molecular-weight methylcellulose-based thermo-reversible gel/pluronic micelle combination system for local and sustained docetaxel delivery Pharm. Res. 29 2012 525 534
111. E. Ruel-Gariépy, M. Shive, A. Bichara, M. Berrada, D. Le Garrec, A. Chenite, and J.-C. Leroux A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel Eur. J. Pharm. Biopharm. 57 2004 53 63
112. A. Chenite, C. Chaput, D. Wang, C. Combes, M. Buschmann, C. Hoemann, J. Leroux, B. Atkinson, F. Binette, and A. Selmani Novel injectable neutral solutions of chitosan form biodegradable gels in situ Biomaterials 21 2000 2155 2161
113. E. Ruel-Gariepy, A. Chenite, C. Chaput, S. Guirguis, and J.-C. Leroux Characterization of thermosensitive chitosan gels for the sustained delivery of drugs Int. J. Pharm. 203 2000 89 98
114. E. Ruel-Gariepy, G. Leclair, P. Hildgen, A. Gupta, and J.-C. Leroux Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules J. Control. Release 82 2002 373 383
115. S. Supper, N. Anton, N. Seidel, M. Riemenschnitter, C. Schoch, and T. Vandamme Rheological study of chitosan/polyol-phosphate systems: influence of the polyol part on the thermo-induced gelation mechanism Langmuir 29 2013 10229 10237
116. C. Li, S. Ren, Y. Dai, F. Tian, X. Wang, S. Zhou, S. Deng, Q. Liu, J. Zhao, and X. Chen Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel AAPS PharmSciTech 15 2014 417 424
117. R.L. Dunn, A.J. Tipton, G.L. Southard, J.A. Rogers, Biodegradable Polymer Composition, in, Google Patents, 1994.
118. W.J. Lambert, and K.D. Peck Development of an in situ forming biodegradable poly-lactide-coglycolide system for the controlled release of proteins J. Control. Release 33 1995 189 195
119. J.R. Weiser, and W.M. Saltzman Controlled release for local delivery of drugs: barriers and models J. Control. Release 190 2014 664 673
120. T. Leung, S. Yu, P. Johnson, J. Geschwind, T. Vogl, K. Engelmann, G. Gores, M. Giovannini, J. O'Grady, and M. Heneghan Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma J. Clin. Oncol. 21 2003 652 658
121. H.A. Burris, C.L. Vogel, D. Castro, L. Mishra, M. Schwarz, S. Spencer, D.D. Oakes, R. Korey, and E.K. Orenberg Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study Otolaryngol. Head Neck Surg. 118 1998 496 503
122. D.J. Castro, K.S. Sridhar, H.S. Garewal, G.M. Mills, B.L. Wenig, F.R. Dunphy, P.D. Costantino, R.D. Leavitt, M.E. Stewart, and E.K. Orenberg Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America Head Neck 25 2003 717 731
123. A. Marabelle, H. Kohrt, C. Caux, and R. Levy Intratumoral immunization: a new paradigm for cancer therapy Clin. Cancer Res. 20 2014 1747 1756
124. Y. Li, B. Li, C.-J. Li, and L.-J. Li Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors Expert. Opin. Biol. Ther. 15 2015 437 454
125. X. Li, S. Xiao, Y. Li, and S. Zhang Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer Chin. J. Cancer Res. 25 2013 749
126. W. Lu, S. Zheng, X.-F. Li, J.-J. Huang, X. Zheng, and Z. Li Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial World J. Gastroenterol. 10 2004 3634 3638
127. J. Heo, Y. Chao, D.J. Jonker, A.D. Baron, F. Habersetzer, J. Burke, C. Breitbach, R.H. Patt, R. Lencioni, and M. Homerin Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE) ASCO Annual Meeting Proceedings 2013 TPS4161
128. T.P. Cripe, M.C. Ngo, J.I. Geller, C.U. Louis, M.A. Currier, J.M. Racadio, A.J. Towbin, C.M. Rooney, A. Pelusio, and A. Moon Phase 1 study of intratumoral Pexa-Vec (jx-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients Mol. Ther. 2014
129. C.J. Breitbach, K. Parato, J. Burke, T.-H. Hwang, J.C. Bell, and D.H. Kirn Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic Curr. Opin. Virol. 13 2015 49 54
130. J.C. Hu, R.S. Coffin, C.J. Davis, N.J. Graham, N. Groves, P.J. Guest, K.J. Harrington, N.D. James, C.A. Love, and I. McNeish A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin. Cancer Res. 12 2006 6737 6747
131. N. Hanna, P. Ohana, F. Konikoff, G. Leichtmann, A. Hubert, L. Appelbaum, Y. Kopelman, A. Czerniak, and A. Hochberg Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer Cancer Gene Ther. 19 2012 374 381
132. L. Buscail, B. Bournet, F. Vernejoul, G. Cambois, H. Lulka, N. Hanoun, M. Dufresne, A. Meulle, A. Vignolle-Vidoni, and L. Ligat First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings Mol. Ther. 2015
133. M. Kowalski, J. Entwistle, J. Cizeau, D. Niforos, S. Loewen, W. Chapman, and G.C. MacDonald A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients Drug Des. Devel. Ther. 4 2010 313
134. G.C. MacDonald, M. Rasamoelisolo, J. Entwistle, J. Cizeau, D. Bosc, W. Cuthbert, M. Kowalski, M. Spearman, and N. Glover A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck Drug Des. Devel. Ther. 2 2008 105
135. G. MacDonald, M. Rasamoelisolo, J. Entwistle, W. Cuthbert, M. Kowalski, M.A. Spearman, and N. Glover A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck Med. Oncol. 26 2009 257 264
136. J.D. Lickliter, B. Panizza, C.S. Karapetis, V.A. Gordon, P.W. Reddell, K.T. Lingard, R.M. Cusack, and P. De Souza Phase 1 dose-escalation study of EBC-46 given by intratumoral injection to patients with refractory cutaneous and subcutaneous tumors ASCO Annual Meeting Proceedings 2015 TPS2616